Search results
Author(s):
John Dodson
,
Harriette Van Spall
Added:
2 months ago
AHA Scientific Sessions 2025 — Late-breaker host Dr Harriette Van Spall (McMaster University, Hamilton, CA) is joined by BETTER-BP Principal Investigator Dr John Dodson (NYU Langone Health, New York, US) to present the findings of this AHA late-breaking trial (NCT04114669).The BETTER-BP (Behavioral Economics Trial to Enhance Regulation of Blood Pressure) is a phase II pragmatic randomized…
View more
Kazuomi Kario
Job title: Professor and Chairman of Cardiovascular Medicine
Author
Author(s):
Rhian Touyz
Added:
1 year ago
ESC Congress 2024 — Dr Rhian Touyz (McGill University Health Center, CA) joins us to discuss key highlights from the ESC 2024 guidelines for the management of elevated blood pressure and hypertension.The new guidelines introduce a new systolic blood pressure treatment target range of 120-129 mmHg, placing emphasis on an intensive target treatment as the first step in patient management - only…
View more
Author(s):
Maria Lorenza Muiesan
Added:
10 months ago
Author(s):
Maria Lorenza Muiesan
,
Matteo Lemoli
Added:
2 months ago
Clinical Clues in Cardiovascular Disease
Video Series
Author(s):
Giacomo Buso
,
Claudia Agabiti-Rosei
,
Matteo Lemoli
,
et al
Added:
1 year ago
Author(s):
Nicolas M Van Mieghem
Added:
2 months ago
Stay at the forefront of cardiovascular medicine with our comprehensive video collection from the American Heart Association's Scientific Sessions 2025. Access expert analysis of the most impactful late-breaking trials and featured science shaping clinical practice.Late-Breaker Discussions: Watch Dr Harriette Van Spall break down pivotal clinical trial data and explore its implications for…
View more
Author(s):
Nicolas M Van Mieghem
,
Joost Daemen
Added:
1 year ago
What’s hot at ACC.24?Join interventional experts, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL) to learn more about this year’s key late-breaking and featured science trials that have the potential to shape practice and research.This preview episode of View from the Thoraxcenter offers a critical analysis of the most anticipated trials of ACC.24,…
View more
Author(s):
Harriette Van Spall
,
Luke Laffin
Added:
9 months ago
ACC 25 - ADVANCE-HTN shows lorundrostat, an aldosterone synthase inhibitor, effectively lowered 24-hour blood pressure in patients with uncontrolled and true resistant hypertension.Late-breaker discussion host, Dr Harriette Van Spall (McMaster University, Hamilton, CA) is joined by Dr Luke Laffin (Cleveland Clinic, Cleveland, OH, US) to discuss the key findings from the ADVANCE-HTN trial…
View more